Greenback Rises on Fed-Tapering Speculation, Aussie Drops

By HY Markets Forex Blog

The greenback advanced against most of its peers as investors continue to speculate that the US Federal Reserve (Fed) will reduce its bond purchases further at its next meeting scheduled for January 28-19, after data released showed signs that the world’s biggest economy is growing at a slow pace.

Meanwhile the Japanese yen is rising towards its biggest weekly advance in five-months, while the demand for Japanese assets were driven by the increased scrutiny of credit risks in China’s coal-mining industry.

The Australian dollar dropped to its lowest level against the greenback since July 2010. Following the comments from Heather Ridout, Reserve Bank of Australia (RBA) board member.

A report released yesterday revealed the figures for people in the US receiving unemployment benefits increased higher than expected.

The US dollar rose 0.1% higher to $1.3682 per euro; it also gained 0.1% to 103.37 yen. The Japanese yen remained unchanged at 141.44 against the 18-bloc currency.

The Australian dollar slid 0.7% lower to $87.07 after reaching 86.89, the lowest in three and a half years.

Fed- Taper Speculations

Market analysts are predicting members of the Federal Open Market Committee will reduce its monthly bond purchases by $10 billion at every meeting to end the stimulus program by December year. The Federal Open Market Committee (FOMC) next policy meeting scheduled for January 28-29.

The figures for people in the US receiving unemployment benefits unexpectedly increased to 3.06 million in the period ended January 11, the most since July, reports from the Department of Labour confirmed yesterday. Analysts forecasted a decline of 2.9 million after the Labour Department data revealed the economy added 74,000 jobs in December.

Yen

This year, the Japanese currency was the best performer; climbing 1.9% higher against the US dollar. Following the 18% drop in 2013, the worst among a basket of 10 of its major peers.

“We have come quite a ways higher in dollar-yen,” Citigroup’s Elmer said. “It doesn’t seem exaggerated to me that we would see a flush-out of positions close to a big figure, but I don’t think that shifts the trend,” he added.

AUD & RBA Comments

The Australian currency dropped to a three-and-a-half-year low on Friday, after an external board member commented on the currency.

External board member of the Reserve Bank of Australia, Heather Ridout said she sees the Australian dollar dropping lower to help re-balance the Australian economy from slowdown. The Aussie was dragged lower by the comments made and the downbeat Chinese manufacturing data.

The Australian dollar slid 0.7% lower to $87.07 after reaching 86.89, the lowest in three and a half years.

 

Visit www.hymarkets.com   to find out more about our products and start trading today with only $50 using the latest trading technology today.

The post Greenback Rises on Fed-Tapering Speculation, Aussie Drops appeared first on | HY Markets Official blog.

Article provided by HY Markets Forex Blog

Gold Slides From Six-Week High

By HY Markets Forex Blog

Gold Futures dropped from a six-week high on Friday on speculation higher prices could reduce physical demand and the Federal Reserve could reduce its monthly bond purchases further at the next meeting.

Gold for immediate delivery dropped 0.32% to $1,258.10 an ounce on the New York’s Comex at the time of writing, falling from recent highs of $1,267 an ounce seen on Thursday, the highest since December 10. While silver futures edged up 0.15% to $19.98 an ounce.

Gold- FOMC

With the anticipating FOMC meeting approaching, the previous metal has been under pressure as the meeting may reducing the monthly asset purchases by an additional $10-billion trim.

Members of the Federal Open Market Committee (FOMC) are expected to meet for the next policy meeting scheduled for January 28-29.  In the last fed-meeting, the central bank decided to reduce its monthly bond purchases by $10 billion to $75 billion a month.

Market analysts are predicting members of the Federal Open Market Committee to reduce its monthly bond purchases by $10 billion at every meeting to end the stimulus program by December year.

Gold – China

Meanwhile in China, premiums on the Shanghai Gold Exchange slid $9 an ounce from Thursday’s $12, reports confirmed. Market analysts predict that China probably overtook India as the world’s biggest gold consumer last year.

China will be celebrating the Lunar New Year Holiday at the end of the month.

Indian Finance Minister Palaniappan Chidambaram said that gold imports will be curbed into the next financial year from April 1.

 

Win a luxurious trip to the Maldives & up to $30,000 cash for trading with us!

Visit for details http://ift.tt/L42Q3q

The post Gold Slides From Six-Week High appeared first on | HY Markets Official blog.

Article provided by HY Markets Forex Blog

Fibonacci Retracements Analysis 24.01.2014 (EUR/USD, USD/CHF)

Article By RoboForex.com

Analysis for January 24th, 2014

EUR/USD

Euro rebounded from correctional level of 61.8% and started moving upwards, that’s why during the next several weeks it better to buy than to sell. Most likely, in the nearest future price will break maximum. Main target is close to several upper fibo-levels, near 1.3970.

At H1 chart we can see, market is being corrected, but this correction is unlikely to be very deep. Most likely, during the day price will reach level of 23.6%. If pair rebounds from it, I’ll open one more buy order.

USD/CHF

Franc rebounded from level of 78.6%. Now bears are in charge and may break minimum quite soon. Target is in area formed by levels of 123.6% and 100%, close to 0.8710.

As we can see at H1 chart, market is being corrected. According to analysis of temporary fibo-zones, local level of 23.6% may be reached quite soon. If price rebounds from this level, bears will continue pushing pair downwards.

RoboForex Analytical Department

Article By RoboForex.com

Attention!
Forecasts presented in this section only reflect the author’s private opinion and should not be considered as guidance for trading. RoboForex LP bears no responsibility for trading results based on trading recommendations described in these analytical reviews.

 

 

 

Japanese Candlesticks Analysis 24.01.2014 (EUR/USD, USD/JPY)

Article By RoboForex.com

Analysis for January 24th, 2014

EUR/USD

H4 chart of EUR/USD shows support from lower Window. Hammers and Belt Hold patterns, along with Three Line Break chart and Heiken Ashi candlesticks, confirm ascending movement.

H1 chart of EUR/USD shows resistance from upper Windows. Three Line Break chart confirms ascending movement; Shooting Star pattern and Heiken Ashi candlesticks indicate possibility of new correction.

USD/JPY

H4 chart of USD/JPY shows descending movement, which is indicated by Shooting Star pattern. Three Line Break chart and Heiken Ashi candlesticks confirm bearish mood.

H1 chart of USD/JPY shows resistance from closest Window. Three Methods pattern, Three Line Break chart, and Heiken Ashi candlesticks confirm descending movement.

RoboForex Analytical Department

Article By RoboForex.com

Attention!
Forecasts presented in this section only reflect the author’s private opinion and should not be considered as guidance for trading. RoboForex LP bears no responsibility for trading results based on trading recommendations described in these analytical reviews.

 

 

 

The Last Word: Place Your Biotech Bets on Solid Management and Hot Therapy Areas

Source: Tracy Salcedo-Chourré of The Life Sciences Report (1/23/14)

http://www.thelifesciencesreport.com/pub/na/the-last-word-place-your-biotech-bets-on-solid-management-and-hot-therapy-areas

Who got the last word at the 2014 Biotech Showcase? A portfolio manager specializing in healthcare, an award-winning analyst, and a pair of venture capitalists with global viewpoints and a focus on clinical-stage companies. In the closing event of the showcase, cohosted by The Life Sciences Report, this panel of experts offered insights into trends that will influence the biotech universe in 2014.

San Francisco was the center of the life sciences universe last week, hosting three industry conferences under shockingly blue skies. In addition to the JPMorgan Healthcare Conference, Biotech Showcase 2014, with its focus on small- and mid-cap public and private biotech firms, drew thousands of participants.

The Life Sciences Report launched its 2014 Biotech Watchlist at the showcase, and cohosted the closing reception, “The Last Word,” a panel discussion on the state of the industry from the perspective of earlier-stage biotech and medtech companies. Moderated by Kimberly Ha, BioPharm Insight’s global editor, panelists included Steve Brozak, president of WBB Securities LLC, a boutique investment bank and research firm, Fabrice Egros, managing partner with RMI Partners (cohost of the panel), a global life sciences venture capital investment firm, Dhesh S.K. Govender, portfolio manager for healthcare with Cedar Lane Enterprises and Anthony Sun, a partner with Aisling Capital, a private equity fund.

The first words of the Last Word panel addressed the wealth of potential in smaller, nimbler biotech companies, and how a burgeoning number of acquisitions and partnerships in 2013 reflected the interest of big pharma in ideas generated by these smaller enterprises. As Brozak pointed out, the “scarcity of new products and new technology” within the pipelines of larger pharmas had brought “people from JPMorgan shopping for ideas” at the Biotech Showcase.

Nurturing the Small-Cap Biotech Boom

The biotech boom has been good to small-cap firms with innovative technologies and the ability to move their products to market. As these companies progress through clinical trials and clear regulatory hurdles, their stock prices typically increase. Stock prices also jump when bigger pharmas and biotechs become interested: With partnerships and pending acquisitions come increases in valuation.

Govender expects the partnership and acquisition theme to continue into 2014. In fact, within the next few weeks, he said the market could expect to see “18–22 deals.” Will the doubling and tripling of valuations continue as those deals are made? “The next couple of weeks will tell,” Govender said, adding that companies run by management teams with experience as dealmakers, good fundamentals and a product that addresses a good market, will be premium targets. Big pharma, he predicts, will set records for amounts paid for early-stage assets in oncology, especially checkpoint inhibition.

But the panelists agreed that, barring partnership or acquisition, financing early-stage biotechs would not get easier any time soon. Sun cited a lack of appetite on the part of venture capitalists and the public market for companies with products in early days. In addition, it’s difficult to “nail down a valuation” for early-stage companies, Govender said.

Management, Management, Management

The panelists were universal in their belief that biotechs with good management are an investor’s best bet. Investors who get to know a company’s management team will be able to find a deal they can get behind, Brozak said.

Those management teams also need to hone their pitches when looking for financing. In terms of the “X-factor” that the panelists look for when considering a company, Sun wants to see “a clear plan, with a clear number of milestones or an exit.” For Brozak, management has to be able to deal with regulatory setbacks, personnel problems and the like. Govender likes to see a “clear understanding of the marketplace across the globe,” an idea that Egros echoed, citing his desire that management have a “worldwide vision” for an idea.

The panelists also agreed that they liked to see companies led by teams that have track records of successful exits. While sometimes “first-timers have done other things that bring new perspective” to a biotech, there is great comfort for investors in knowing they are “dealing with someone who has succeeded before,” Brozak said.

Tapping into Therapy Areas

While individual small companies with no proof of profitability may not interest venture capitalists (VCs) at present, Brozak said that therapy areas might garner “more of a sizzle,” with VCs picking a basket of preclinical or phase 1 companies.

2013 was a “record-setting” year for drug development in oncology, Egros observed, and he expects that trend to continue into 2014. Following on this idea, Sun mentioned targeted oncology as a field with great potential.

Brozak was enthusiastic about the prospects of companies working in the antibiotic space. With bugs becoming resistant to the “simple antibiotics” currently available, companies looking for new solutions using new technologies offer great promise.

The prospects for personalized medicine, especially given advances in gene sequencing—and in particular the promise that costs associated with sequencing will decrease as numbers reach “critical mass”—were intriguing to Govender.

Ha piggybacked on the mention of gene sequencing, asking how the “$1,000 genome” will affect drug development.

If small companies are able to pass that price on to a partner, Brozak said, they’d have the “best of both worlds,” both reducing development costs and gaining access to a “quicker model of discovery.” An inexpensive genome would impact trial design as well, Sun added.

“It levels the playing field,” Govender said.

Enter Emerging Markets

Emerging global markets present a challenge for biotech investors, in part because the matrices used to calculate valuations for companies vary from country to country. Sun delineated two issues investors would want to investigate prior to investment: Generally accepted accounting practices (GAAP) would need to be addressed, and the device or drug would have to be differentiated from devices/drugs on the domestic front.

In addition, Brozak noted that in some cases, cultural uses for therapies are very different, which affects valuation. He cited Japan as an example, where the use and design of antivirals are different from what is found in the United States.

Still, international markets, particularly those in Australia, Israel and Europe, will present opportunities for investors going forward, according to Govender. Likewise the BRIC (Brazil, Russia, India, China) market, which Egros noted “is moving ahead much faster than Europe, and is becoming a fast follower of the U.S.”

Something New: Wearable Technology

The “new buzz” surrounding wearable medical devices capable of monitoring and transmitting personal health information, such as the Fitbit wristband, prompted Ha to ask the panelists how they felt these devices would affect the industry.

Reaction was mixed. Brozak noted that the technology “lends itself to personalized medicine,” providing real-time information about whatever is being tracked by the device, whether the monitoring of symptoms or the dosage and/or effects of drugs. But, “How do you control data mining?” he asked.

Sun felt the adoption of wearable technology by providers would be “slow.” The technology would have to be economically viable, and insurance companies would have to buy in. As for the use of wearable devices in clinical trials, Sun said a company likely wouldn’t want that kind of data until it knows its drug works.

The Takeaway

Ha ended the session by asking the panelists if they came away from the San Francisco conferences having been struck by a particular insight. For Govender, it was the idea that investors should be “going long” with regard to biotech, since the “shorts are getting crushed.”

Sun was struck by the stunning increases in valuation of Intercept Pharmaceuticals Inc., maker of therapeutics that address chronic liver disease, which could portend explosive growth for some companies in 2014. Intercept has since retreated from its high point.

Egros cited the abundance of initial public offerings, both past and future, as “excellent news” for investors and the industry.

And Brozak concluded with the story of Celgene, which was a tiny company in 1999 when it started investigating thalidomide, at the time a much-maligned drug. But research revealed a “different paradigm” for the therapy as a cancer fighting agent, and the company rocketed from a $150 million market cap to a valuation of almost $70 billion.

“This is America,” Brozak said. “One company at this conference—maybe one of the regenerative medicine companies—could do the same thing. . . .It can happen again.”

January 2013 Biotech Watchlist

PDUFA? What’s a PDUFA? Understanding the Drug Development Process Is Key to Biotech Investing

Steve Brozak is a top-ranked analyst in biotechnology according to the Starmine ranking system. He has been in the securities industry for more than 20 years, where he has held positions in sales, management, investment banking, and research analysis. He has been intimately involved in providing research on a number of companies. Brozak has a bachelor’s degree and a master’s degree in business administration from Columbia University and is a retired lieutenant colonel in the United States Marine Corps.

Fabrice Egros, managing partner with RMI Partners, has more than 20 years of international experience of work in the pharmaceutical industry. Prior to coming to NovaMedica he held managerial positions at Xanodyne, UCB (in Belgium, the U.S. and Japan). Egros also worked at Parke-Davis/Warner Lambert in Germany and the U.S. and Sanofi-Aventis in Japan and the U.S. His responsibilities have encompassed clinical development, marketing, market access, sales, business development and general management functions. Egros received his Pharm.D and Ph.D in pharmaceutical sciences degrees at Chatenay Malabry University (Paris), a diploma in business administration from Schiller International University (Dunedin, Florida) and studied in the advanced management program at Harvard University.

Dhesh S.K. Govender is a portfolio manager for healthcare and life sciences with the Cedar Lane Fund, a division of New York-based Cedar Lane Enterprises.

Anthony Sun joined Aisling Capital’s Fund I in 2002 and currently serves as a partner. Previously, Sun was an adjunct instructor of medicine at the Hospital of the University of Pennsylvania. Sun currently serves as a director of Paratek Pharmaceuticals Inc. and Versartis Inc. Previously he served as a director of CeNeRx BioPharma Inc., Dynova Laboratories Inc., HerbalScience Inc. and MAP Pharmaceuticals Inc. Sun received his M.D. from Temple University School of Medicine with honors. He received his master’s degree in business administration from The Wharton School at the University of Pennsylvania, and his bachelor’s degree in electrical engineering from Cornell University. In addition, he is board certified in internal medicine.

Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.

DISCLOSURE:

1) Tracy Salcedo-Chourré prepared this article for The Life Sciences Report and provides services toThe Life Sciences Report as an independent contractor. She or her family own shares of the following companies mentioned in this interview: None.

2) The following companies mentioned in the interview are sponsors of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services.

3) Articles are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.

6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

Streetwise – The Life Sciences Report is Copyright © 2014 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part..

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.

101 Second St., Suite 110

Petaluma, CA 94952

Tel.: (707) 981-8204

Fax: (707) 981-8998

Email: [email protected]

 

 

 

Knock Knock. Who’s There? …China’s Metal Monopoly

By MoneyMorning.com.au

I hope you’re hunkered down from the big chill this month. Wow, we’ve seen some cold. It was so cold a few weeks ago that one of my cats stuck his face outside one morning and literally jumped back into the house. Cold, right?

And here we are with another polar vortex breathing down our neck. It’s ‘historic cold’, said the weather guy on television. Something to look forward to, I suppose.

Meanwhile, let’s take a look at a metals sector that’s still poised to heat up…

Earlier this month, The Wall Street Journal ran an article by a member of its staff, Joseph Sternberg, entitled ‘How the Great Rare Earth Metals Crisis Vanished‘. The article was on the editorial page. Then again, the WSJ doesn’t do horoscopes and astrology. Still, my question is why the WSJ ran an article that’s so off base and misleading.

Here’s my take on this ‘rare’ metals sector…

Mr. Sternberg began by describing China’s rare earth (RE) export embargo against Japan in 2010. Mr. Sternberg basically got that part correct. The Chinese 2010 embargo was due to a disputed boundary with Japan – and really, are there any other kinds of China-Japan boundaries? The two countries are arguing over everything.

Now, if you follow East Asia news, that set of China-Japan boundary issues is ongoing. Right off the bat, I believe that we could still see future Chinese RE embargoes. But that’s not really my focus here.

My beef with Mr. Sternberg began when he wrote, ‘Global [RE] prices rose dramatically [in 2010], creating an incentive for new miners to start production, and an opportunity for them to profit.

Well, yes and no. Prices rose in 2010 and 2011, to be sure. Then prices fell dramatically over the next two years, for a variety of reasons. Meanwhile, today, in 2014 – three years later – there’s almost no new, non-Chinese RE production on the global market. There’s certainly nothing much from new miners in the West.

Moving along, it’s accurate to say that nobody in the new miner RE arena is making any money. In fact, most new, Western (i.e., non-Chinese) RE plays that are still in business are cash burners. Most are far from cash flow, let alone profitability.

Mr. Sternberg also writes that ‘New supplies for most rare earths are coming online, as uncertainty over China’s reliability and a period of higher prices stimulated investment in new mining projects elsewhere.

No, that’s not what happened or what’s happening. New supplies for most RE are NOT ‘coming online’. This is especially the case for heavy RE elements (i.e., RE elements with high atomic numbers). These RE are used as lighting phosphors and in high-end electronics. Even the magnet-oriented RE elements are still in tight long-term supply.

Western RE users remain nervous about China’s reliability as a long-term supplier. But contrary to Mr. Sternberg’s positive implication for the future, the RE crisis is not resolving, let alone has it somehow ‘vanished’. The Chinese still hold the trump card when to comes to RE production – they still produce over 95% of the world’s supply.

Doing RE Is Hard Work

Any new RE project makes for very hard, expensive work. Indeed, most non-Chinese RE projects of recent vintage are barely past the drilling and assay stage. There are a number of Canadian-compliant 43-101 resource estimates floating around, and the odd pre-feasibility study. But the industrial world is a long way from banking and building any new mining projects outside China. They’re not there. Not even close.

This last point barely scratches the surface of what happens after a Western firm receives permission to open or build a mine – from a long list of flinty government entities, I must add, among whom many players can say no. Along the way, mining company managers have to multitask and juggle financing, design, pilot-scale testing, construction, build-out and final testing.

Perhaps someday, one or more RE wannabes will even process some ore and make what’s called a concentrate. Then after that, there’s complex downstream chemistry, which is a combination of Ph.D.-level industrial effort, innumerable trade secrets and just plain metallurgical black art. There’s nothing easy about any of this, at any stage.

The Missing Western Supply Chain

Through it all, there’s very little in the way of a non-Chinese RE supply chain, in any sense of the word. There are very few Western companies with the actual background, engineering skill and know-how to design and build RE systems. There are almost no universities in the U.S. or Canada with dedicated RE educational pipelines. (Colorado School of Mines started a focused RE program all of two years ago.)

Any Western RE business wannabe has to kick down doors (figuratively, but maybe literally in some instances) to convince potential users/customers to take significant risks and make an early-stage deal. Whatever the frustrations, however, it’s necessary for the upstream miner to work with the eventual downstream RE user early on to determine exactly what kind of end-product to supply.

Why must miners and customers/users get together so early? Because iron ore is iron ore, copper is copper and gold is gold. But almost every application for RE is different and unique.

That is, every light bulb maker has a different approach to specifying its RE phosphor. Every electronics maker has a different approach to what it wants. Every magnet maker has its own secret formula. In short, things get down to the molecular shape of the RE oxide or salt coming out of a metallurgical process, and there’s much that’s simply unknown to early-stage developers. You just have to start early or you’re wasting time and money.

It’s NOT Resolved!

So no, contrary to the WSJ, the RE crisis has not resolved, let alone ‘vanished’. The market is still poised for a 2010-style melt up. Here in the Western world, there’s generally more awareness of how RE fit into modern industry and defense applications. It’s better now than just a few years ago. But today, there’s virtually no more physical RE product – not from a non-Chinese supply chain, that is.

There are opportunities to play this monopolized market, if you know where to look. But rest assured these are specialised plays. I’d steer clear of the market darlings, like Molycorp, and look to smaller, focused opportunities.

Looking ahead, Western RE users had better hope that any number of these small, focused mineral and processing plays can make it through the next few years, after a totally miserable 18 months in the junior resource market. Because right now, that’s what’s out there. Otherwise, we had all better brush up on our Mandarin.

Byron King,
Contributing Editor, Money Morning

Ed Note: The above is an edited version of an article originally published in Daily Resource Hunter.

Join Money Morning on Google+


By MoneyMorning.com.au

Monkey Derivatives won’t pay you in Retirement, but this could

By MoneyMorning.com.au

Eleven years ago Warren Buffett’s Berkshire Hathaway underwrote an insurance policy for a US$1 billion game show prize.

In return for underwriting the prize, Berkshire Hathaway received a US$10 million premium.

Despite the risk, the odds of Buffett’s firm having to pay out on the prize were slim, one million to one. In order to win the prize, the contestants had to have the same six-digit number as that selected at random…by a chimpanzee.

It’s no surprise that the contestants didn’t come close to winning this ‘monkey derivative’ as a Bloomberg reporter labelled it (we’ll excuse the reporter’s error in confusing a monkey with a chimp). The billion-dollar prize went unclaimed and Warren Buffett’s Berkshire Hathaway got to keep the US$10 million premium.

Well, despite his reputation as a conservative value investor it seems Buffett’s appetite for risky bets hasn’t diminished. This week Berkshire Hathaway revealed it’s underwriting another billion-dollar bet…

This time the bet appears even safer. In order to claim the prize the winner needs to correctly predict the winning team in all 67 games of the US NCAA college basketball tournament.

The odds of anyone winning are nine quintillion to one (that’s a 9 with 18 zeros!).

It’s not clear how much Berkshire Hathaway will receive in premiums this time. But it’s likely to be in the millions of dollars.

If you’ve got the capital to guarantee a one billion dollar prize pool in return for a few million dollars in premiums on events with an almost impossible chance of occurring, then heck, that’s a good money-spinner.

But these types of opportunistic income streams aren’t available to most investors. Most investors have to rely on more conventional ways to earn an income.

However, if you put your mind to it, there is a way to create an income stream where, like the Buffett bets, the odds are stacked in your favour – and thankfully it doesn’t involve chimps or monkeys…

Retirement Isn’t Just About Saving

Our old buddy Nick Hubble is one of the smartest thinkers we know.

He’s always coming up with intriguing ways for investors to safely save for retirement. But saving for retirement is only half the story.

It’s also important for retirees to earn money in retirement without taking unnecessary risks.

It’s something most people don’t think about. They think that once they’ve saved a bunch of cash during their working lives that’s where things end. But it’s not.

Earning an income in retirement is just as important as earning an income during your working life. Here’s why.

Don’t Sell Your Capital

Think about it this way. If you gave up work today, how would you fund your lifestyle?

If you don’t have an income you’d have to sell your possessions – your home, car, jewellery, furniture, and so on. That would probably get you by for a while. But what would you do after you’ve sold every last thing you own?

You’d have to go back to work. That may be easy to do when you’re in your 30′s, 40′s, or even 50′s. It may not be so easy when you’re in your 60′s, 70′s or 80′s.

The simple fact is that if you have to use your capital, you’re slowly eating away at your income producing assets. And once you’ve sold your capital you can’t earn an income from it.

That’s where Nick’s income strategy enters the frame.

Our view is that investors should have up to half of
their investible assets in stocks. This should be a combination of growth and income stocks.

The rest of your investible assets should be in a combination of cash and gold. The amount you decide to allocate to each of these asset classes is up to you depending on such things as your attitude to risk and your age.

The problem with stocks of course is that sometimes they can fall in value. Falling markets usually happen because company profits fall. When company profits fall it can result in lower dividend payouts, which can mean a lower share price.

If you’re a retiree who depends on dividends for income that can be a problem. If the dividends no longer meet your living expenses you may have to sell shares to make up the difference. Except of course, if the share price has dropped you have to sell your shares at a lower price than you’d like.

That’s a double punch in the teeth, because as we mentioned before, if you sell your capital it means you’re selling an income-producing asset at a knockdown price.

Another Way to Earn Income

That’s where Nick came up with the idea of what he calls a ‘security ladder’.

He explains how it works in a report he’s prepared for Money Morning readers. You can check out the details here.

Simply put, it’s a neat strategy that involves investing in a particular type of security (not shares) that’s almost guaranteed to pay you a return.

In fact, you could even say it’s a ‘government-backed’ guarantee. Of course, that doesn’t have the same cast-iron assurance that it used to have. But where these particular securities are concerned, government backing does count for something.

Frankly, Nick’s ‘security ladder’ strategy is about as good as it gets when it comes to locking in a steady income stream.

Hitting retirement and then working out how to pay for your lifestyle for another 20, 30 or even 40 years after you retire can be a daunting thought. And planning for it isn’t something you should take lightly.

So if there was a way to reduce the worry and invest in a secure and reliable income stream, without having to worry about the ups and downs of the stock market, well, we can’t think of a single person who wouldn’t want that level of income security.

We love stocks as a great way to earn an income. But we also know they can be risky and volatile at times. Nick’s strategy doesn’t replace stocks. It’s a complementary way to achieve a virtually guaranteed income stream during times of stock market volatility.

It’s worth checking out.

Cheers,
Kris+

Special Report: 2014 Predicted

Join Money Morning on Google+


By MoneyMorning.com.au

Do This Before Trading A Live Forex Account

 

Core Liquidity Markets

Opening a live Forex account is a big step for beginner traders. Forex markets are a great way to invest, but there is a lot of risk involved, so you need to know you’re ready before you open a live account. Before opening, you should have chosen a platform and traded successfully with a demo account. You need a strong, written trading system, and some capital you can afford to lose. You also need to prepare for the mental pressure of trading with real money.

1. A Demo Account

Run a profitable demo account for at least a couple of weeks before opening a live account. If you can’t make money with a forex demo account, you won’t make money using a live account. A demo account tests your trading strategies, mental strength and financial management without the risk and expense of a live account. Fixing a mistake on a practice account is as simple as opening a second account. Fixing a mistake on a live account costs real dollars.

2. A Tested Trading System

Your trading system is what makes you money. Without one, you are gambling on the market moving in the right direction. Good traders analyze trades and track results carefully. Write your trading system down on a piece of paper with clear, unambiguous signals for entry and exit points. As you trade your demo account, hold yourself accountable to these signals and record when and why you deviate from them. If you don’t use a system, you will lose money.

3. Capital You Can Afford To Loose

The money you deposit in your Forex account should be money you can afford not to get back. Even the most experienced traders have losing streaks, and so don’t be surprised if you start on one. Many traders have profitable forex systems, but it takes time to build your small initial investment to a large fortune, and trying to get rich quick is as good as throwing your money into a wishing well. If you’re starting off with a small investment, wiping out your account is a very real possibility. Don’t let it leave you in a financial bind.

4. A Risk Management Plan

All investments involve some risk of loss, but forex carries more than most. Successful traders limit their losses if a trade goes against them. In fact, most traders are wrong about half the time, but successful traders are just better at limiting their losses than unsuccessful traders. Without risk management, you are in danger of triggering a margin call when the money leaves your account, taking away any chance you have of making a profit.

5. Mental Strength

Forex success requires tremendous self-discipline. Trading real money is an emotional rollercoaster. You need the presence of mind, mental stability and patience to stay controlled under extreme pressure. It takes a long time to develop this strength, and it should be done with a practice account. After all, if you can’t follow your trading system with a practice account then a live account will only make it worse.

If you have the mental strength, capital and practice, it may be time to open a live account. If you’re struggling with your demo account, spend a little more time practicing before taking the plunge. Opening a trading account before you’re ready is like writing a check to your broker, and you only want to do that after you’ve made some money.

To learn more please visit www.clmforex.com

Disclaimer: Trading of foreign exchange contracts, contracts for difference, derivatives and other investment products which are leveraged, can carry a high level of risk. These products may not be suitable for all investors. It is possible to lose more than your initial investment. All funds committed should be risk capital. Past performance is not necessarily indicative of future results. A Product Disclosure Statement (PDS) is available from the company website www.clmforex.com. Please read and consider the PDS before making any decision to trade Core Liquidity Markets’ products. The risks must be understood prior to trading. Core Liquidity Markets refers to Core Liquidity Markets Pty Ltd. Core Liquidity Markets is an Australian company which is registered with ASIC, ACN 164 994 049. Core Liquidity Markets is an authorized representative of Direct FX Trading Pty Ltd (AFSL) Number 305539, which is the authorizing Licensee and Principal.

 

 

 

Get Positioned Now for the Next Great Natural Gas Switch: Ron Muhlenkamp

Source: Tom Armistead of The Energy Report  (1/23/14)

http://www.theenergyreport.com/pub/na/get-positioned-now-for-the-next-great-natural-gas-switch-ron-muhlenkamp

Cheap natural gas means Americans can buy the equivalent of a barrel of crude for $35. That’s the exciting reality that has Ron Muhlenkamp, founder and portfolio manager of Muhlenkamp & Co. Inc., putting his investment dollars behind the next great fuel switch, this time in the transportation sector. With his fund having finished 2013 with a tidy 34.4% gain, he is now eyeing companies poised to outfit the U.S. transportation sector with all things natural gas, from fuel tanks to motors to filling stations. And let’s not forget the folks who get it out of the ground. As Muhlenkamp tells The Energy Report, we’ve only just begun, so there’s plenty of room to run with well-positioned companies.

The Energy Report: Ron, welcome. You are making a presentation at the Money-Show conference in Orlando in late January. What is the gist of your presentation?

Ron Muhlenkamp: The gist of my presentation is that natural gas has become an energy game changer in the U.S. We are cutting the cost of energy in half. This has already happened for homeowners like me who heat their homes with natural gas. We think the next up to benefit is probably the transportation sector.

TER: What is behind this game change?

RM: The combination of horizontal drilling and fracking has made an awful lot of gas available cheaply. There’s a whole lot of gas that’s now available at $5/thousand cubic feet ($5/Mcf) or less. I live in Western Pennsylvania, and 30 years ago, Ray Mansfield was in the oil and gas drilling business, having retired from the Steelers. He said, Ron, we know where all the gas is in Pennsylvania; it’s just a matter of price. If the price runs up, we will drill more. If the price runs down, we will drill less. Any way you slice it, we are just sitting on an awful lot of it.

Two years ago, we had a warm winter, and the price of gas actually got down to $2/Mcf. You saw an awful lot of electric utilities switch from coal to gas. Literally in a year, what had been 50% of electricity produced by coal went to 35%. The difference was made up with natural gas.

In transportation, the infrastructure to make the switch to natural gas has not been in place. We didn’t have the filling stations or the trucks. Now, the trucks are just becoming available. You can buy pickup trucks from Ford Motor Co. (F:NYSE) and General Motors Co. (GM:NYSE) that run on natural gas. Furthermore, Clean Energy Fuels Corp. (CLNE:NASDAQ) has established natural gas filling stations coast to coast, every 250 miles on five different interstate highways.

Westport Innovations Inc. (WPT:TSX; WPRT:NASDAQ) has been producing 9-liter (9L) natural gas engines. Waste Management (WM:NYSE) uses 9L engines on garbage trucks and expects 85–90% of its new trucks to be natural gas-fueled. Westport has just come out with 12L engines, which are used for over-the-road trucks. I don’t expect those engines to get adopted as fast as the utility industry made the switch to natural gas, but there has been a fairly rapid adoption in the waste management industry. I think we’re on the cusp of a major trend.

TER: That fuel switching in the power industry has been going on since 2008. Is it still progressing at the same rate or is it picking up?

RM: It’s pretty much leveled off. In fact, there’s probably a little bit less gas used than when gas was below $3/Mcf. The latest numbers I’ve seen show that we’re running about 37% coal and about 33–34% gas. Going forward, I think coal use will continue to decline, and natural gas use will continue to rise. The big switch is over in utilities, and it will be gradual from here. But we’ve barely begun the transition with transportation fuel.

TER: So the game has changed for the power industry, and the transportation industry is next. What other changes do you foresee in the future?

RM: We will continue to use more natural gas and less crude. Right now, for equal amounts of power, crude oil is priced at about three times the natural gas price in the U.S. That is too wide a spread to ignore, economically.

The Natural Gas – Crude Oil Spread

 

source: Bloomberg

 

Incidentally, in Europe, natural gas is still at $12/Mcf. It’s on a par with crude. Most European chemical plants use a crude oil base to make chemicals. U.S. plants use a natural gas base. Natural gas becomes ethane, then ethylene, then polyethylene and then plastic. So producers of plastics or the feedstocks for plastic in the U.S. now have an advantage they didn’t have before.

In Japan, the natural gas price jumped from $12 to $16/Mcf just after the tsunami wiped out the Fukushima nuclear power plant. To ship gas from the U.S. to Japan, the cost of compression, liquefying and decompression is about $6/Mcf. Executives at U.S.-based companies like Dow Chemical Co. (DOW:NYSE) are saying they don’t want the U.S. to export gas because that would drive the price up. But domestic gas consumers already have that $6/Mcf advantage. Meanwhile, in Williston, N.D., the natural gas price is effectively zero. Producers still flare it because they don’t have the pipelines to take it out of the area. So this price advantage will be with us in North America for quite a long time. It’s huge. That’s why we call it a game changer.

TER: So how can investors take advantage of these changes?

 

RM: Well, any number of ways. We hold some fracking services companies, like Halliburton Co. (HAL:NYSE). We own a couple of drillers, including Rex Energy Corp. (REXX:NASDAQ). And we invest in the people who build natural gas export facilities, such as Fluor Corp. (FLR:NYSE)KBR Inc. (KBR:NYSE)and Chicago Bridge & Iron Co. N.V. (CBI:NYSE).

I already mentioned companies building natural gas-fired engines, including Westport, which makes a kit to modify a common diesel engine. And because natural gas will require new, larger fuel tanks, investing in companies that build natural gas tanks is another way to play it. One of the disadvantages of natural gas versus gasoline or diesel is compressed natural gas takes about three to four times the volume to get the same range. Liquefied natural gas (LNG) takes about two times the volume. Of course, compressed natural gas is stored in pressure tanks, so it takes a pressure tank of larger size. Fuel tank conversions have been almost as expensive as the engine conversions. 3M Co. (MMM:NYSE)has gotten in that business, as has General Electric Co. (GE:NYSE). There’s another outfit called Chart Industries Inc. (GTLS:NGS; GTLS:BSX), which has already run a good bit.

We want a foot in each of these camps because we’re not quite sure who the ultimate winners will turn out to be, but we know what the product lines will have to be. Don’t forget about the companies that own the LNG export facilities—Cheniere Energy Inc.’s (LNG:NYSE.MKT) facility should be up and running in probably 2015, but, again, that stock has run up a good bit, too.

Pipelines will benefit from the switch. One of the biggest pipelines in the country is Kinder Morgan Energy Partners L.P.’s (KMP:NYSE) Rockies Express Pipeline, which stretches from Northern Colorado to Eastern Ohio and ships gas east. Kinder Morgan recently filed to reverse the flow on part of the line. Right now, in Western Pennsylvania, we have a glut of gas. A few months ago, they reversed the flow of the pipeline from the Gulf Coast that used to come up to Western Pennsylvania. There’s a whole lot going on.

 

TER: After some serious oil train derailments in recent months, pressure is building now to increase pipeline capacity, but there is also pressure on producers to reduce flaring, which is happening on a huge scale in the Bakken Shale. How will the economics and the operations of Bakken producers be affected if they can’t flare and pipeline capacity is not increased?

RM: The Bakken is primarily an oilfield; the gas is a byproduct. We hear a lot about the Keystone XL Pipeline, which is meant to carry oil from the Bakken south. I can’t speak specifically, but if you’re going to lay an oil pipeline from the Bakken, you should lay a gas pipeline alongside it. You can ship oil by rail, but it’s not economic to ship gas by rail. One way or another, the oil will be shipped.

TER: Bill Powers, the independent analyst and author of “Cold, Hungry and in the Dark: Exploding the Natural Gas Supply Myth,” says gas prices are going to rise steadily to as much as $6/million British thermal units ($6/MMBtu) because U.S. gas production has peaked and now is now flat or declining. Do you agree with that?

RM: Our production of gas has not peaked and is not declining. We are using fewer rigs drilling for gas, but each well, particularly if you drill horizontally instead of just vertically, is producing so much more gas. Production is not declining and isn’t likely to for at least a decade. At current rates, we can drill in Pennsylvania for another 50 years. Yes, you drill the best wells first but also, over time, you get a little bit better at timing this stuff. I’d be very surprised if the price in the next decade gets over $5/Mcf for any extended period of time because there’s an awful lot of gas that’s very profitable at that price. I’m willing to make that bet with Bill Powers. But even $6/Mcf gas would equate to $55/bbl crude, which is still a huge spread and wouldn’t negate my general argument.

TER: What’s your forecast for gas prices in 2014?

 

RM: My forecast is $4/Mcf, give or take $1. We just had a big cold snap on the East Coast. What used to happen is any time you had a cold winter, the price of gas jumped. For instance, in 2005, when crude was selling about $50/barrel ($50/bbl), gas began the year at about $7/Mcf, which was on par with crude, but in the wintertime, it doubled and ran up to $14/Mcf. The recent cold snap took gas all the way up to ~$4.20/Mcf. Gas is going to be in that range for a long time.

 

TER: Your advice to investors in natural gas is to get exposure to exploration and production companies, service companies and even LNG plant constructors. What about the LNG plant owners, the pipelines and the railroads?

 

RM: The pipelines will do well. They’ve already been bid up. The railroads will benefit from oil and gas, but they’re getting hurt because coal tonnage is way down, CSX Corp. (CSX:NYSE) just reported. So for the railroads, it’s going to be a wash. They’ll haul less coal and more oil. The railroads won’t haul gas. How much oil they haul is an open question. We’re about to tighten restrictions on how tank cars are built.

 

TER: What did well in the Muhlenkamp Fund last year?

 

RM: The fund was up 34.4%. We did very well in biotech stocks. We did very well in financial stocks. We also did well in some energy stocks. Airlines did well for us. Incidentally, airlines benefit big time from cheaper energy, as you know. So it’s fairly diverse.

 

TER: How are you adjusting your portfolio this year?

 

RM: Not too much has changed. We’re no longer finding many good companies that are cheap. So we’re monitoring and adjusting a little bit around the edges. We do think banks have further to go. We think the economy will grow somewhere between 2.5–3% this year. We’ve owned no bonds for the past couple of years, but with the Treasuries now, the interest rates on the longer end are high enough so that savers can get a little bit of return.

 

TER: I was surprised to see a really sharp drop in November for Fuel Systems Solutions Inc. (FSYS:NYSE). Why did that happen?

 

RM: Fuel Systems makes conversion kits for cars to burn compressed natural gas. In places like Pakistan, 40% of the cars run on natural gas; this is not new technology. A number of its customers decided to make these kits in-house. Fuel Systems is a small position of ours, but, yes, it got hit in Q4/13 when it announced that a number of its customers decided to produce their own kits. One of the nice things about this is there’s no new technology involved. We’ve been using natural gas as a power source for generations. What has changed is the amount that’s available reliably at a cheap price.

 

TER: There was another sharp drop in Clean Energy Fuels in October. What happened there?

 

RM: Clean Energy, so far, doesn’t make a profit because it has been shelling out all the money to build all these filling stations. It’s just taking a little longer than people expected. The stock is compelling at these levels. A number of these companies ran. Westport doubled, and we took some profits. It’s now back down, and we should do a Buy rerating. There is volatility in this stuff, but the economics are undeniable. We still managed a 34.4% gain this year, which isn’t bad.

 

Clean Energy has signed a joint venture with Pilot Flying J to build natural gas fueling stations at Flying J truck stops coast to coast. Royal Dutch Shell Plc (RDS.A:NYSE; RDS.B:NYSE) is doing a similar thing in concert with another truck stop operator. For instance, the Port of Long Beach, Calif., passed a rule several years ago that the trucks on the port need to burn natural gas. The Port of Hamburg, Germany, has contracted to put a natural gas-fired power unit on a barge so that when cruise ships come into the harbor, instead of running their own power off their diesel engines and generators, they’ll use this barge to supply power to the cruise ship because natural gas exhaust is cleaner than diesel exhaust.

 

TER: A couple of other companies had surprising drops— Rex Energy and Westport Innovations. Rex rose all year until October or November, when it suddenly dropped. Westport also dropped suddenly. You had a wild ride in your portfolio, didn’t you?

 

RM: We bought Rex at $13/share, and it went to $22 or $23, and it’s now $19. I can live with that. The dips give you a chance to load up again. That volatility is why we have a diversified portfolio. That’s why you don’t just bet on three stocks.

 

As an investor, most of the time what you’re looking for is to find a difference between perception and reality. Today, we have two realities: One is the price of crude oil, and the other is the price of natural gas. So it’s literally an arbitrage if you can buy energy either at the equivalent of $100/bbl or at a third of that. Four-dollar gas is equivalent in energy content to about $35/bbl crude. So I can buy my energy either at $100/bbl or $35/bbl. Economics says that spread is too wide. It won’t necessarily close, but it sure as heck will narrow a good bit. For instance, I own no conventional oil companies. I think the price of oil will be coming down.

 

TER: So what companies in your portfolio look most promising?

 

RM: If you really want to get me excited, we can talk about natural gas, which we’ve been talking about. We could talk about biotechnology, which is exciting but I don’t understand it as well. We can talk about U.S. manufacturing, but that’s basically based on cheaper energy. I just bought more Rex. At these prices, I’m buying Westport. I just bought Chicago Bridge. I just bought KBR.

 

TER: What is your main motivation in buying these companies? Is it just the stock price or is there something about the management of the company or the technology?

 

RM: We’re in the investment business. What we rely on is good companies, and we look to buy them when they’re selling cheaply. Our first measure of how well a company is run is we start with return on shareholder equity. So we like companies that are at least above average in return on shareholder equity. I cannot yet say that about Clean Energy, but we do think Clean Energy is at the forefront of something that’s needed for this transition. We’re always looking for good companies. Then the question is whether you can buy them at a decent price.

 

My phrase is: I want to buy Pontiacs and Buicks when they go on sale. I don’t want a Yugo at any price. I would like to buy Cadillacs, but they don’t go on sale very often. But if I can get Buicks when they’re on sale, I’ll make good money for my clientele. We think that the companies we have are at least Buicks. If we can get them at Chevy prices, that’s when we buy them. I will not pay an unlimited amount for any company.

 

I’ve never seen a company that was so good it didn’t matter what you paid for the stock. To us, value is a good company at a cheap price. Some people bottom fish. They look to see when they can steal companies, and there are times when you can make money that way. But at that point it’s not often a very good business, and there aren’t too many well-run companies at bargain basement prices. So it’s very unusual for us to buy a weak company or a weak industry.

 

TER: Ron, this has been a good conversation. I appreciate your time, and good luck with your Money-Show presentation.

 

RM: Thanks; it’ll be fun.

 

Ron Muhlenkamp is the founder and portfolio manager of Muhlenkamp & Co. Inc., established in 1977 to manage private accounts for individuals and institutions. In 1988, the company launched a no-load mutual fund as an investment vehicle for all investors, large or small. Muhlenkamp is an award-winning investment manager, frequent guest of the media, and featured speaker at investment shows nationwide. His work since 1968 has been focused on extensive studies of investment management philosophies, both fundamental and technical. As a result of this research, he developed a proprietary method of evaluating both equity and fixed-income securities, which continues to be employed by Muhlenkamp & Co. In addition to publishing his quarterly newsletter, Muhlenkamp Memorandum, he is the author of “Ron’s Road to Wealth: Insights for the Curious Investor.” Muhlenkamp received a Bachelor of Science degree in engineering from M.I.T. in 1966, and a Master of Business Administration degree from the Harvard Business School in 1968. He holds a Chartered Financial Analyst (CFA) designation.

 

Want to read more Energy Report interviews like this? Sign up for our free e-newsletter, and you’ll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Interviews page.

DISCLOSURE:
1) Tom Armistead conducted this interview for The Energy Report and provides services to The Energy Report as an independent contractor. He or his family owns shares of the following companies mentioned in this interview: None.
2) The following companies mentioned in the interview are sponsors of The Energy Report: Royal Dutch Shell Plc. Streetwise Reports does not accept stock in exchange for its services or as sponsorship payment.
3) Ron Muhlenkamp: I or my family own shares of the following companies mentioned in this interview: General Motors Co., Clean Energy Fuels Corp., Westport Innovations Inc., Halliburton Co., Rex Energy Corp., KBR Inc., Chicago Bridge & Iron Co. N.V. and General Electric. I personally am or my family is paid by the following companies mentioned in this interview: None. My company has a financial relationship with the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview. Comments and opinions expressed are my own comments and opinions. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
4) Interviews are edited for clarity. Streetwise Reports does not make editorial comments or change experts’ statements without their consent.
5) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer.
6) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.

 

Streetwise – The Energy Report is Copyright © 2014 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.

 

Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.

 

Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.

 

Participating companies provide the logos used in The Energy Report. These logos are trademarks and are the property of the individual companies.

 

101 Second St., Suite 110
Petaluma, CA 94952

Tel.: (707) 981-8204
Fax: (707) 981-8998
Email: [email protected]

 

 

 

Day Trading As A Business How To

By Jan de Wit

It is often suggested that with your extra capital you should make a long term investment in stocks and shares. Investing this way allows you to gain profit upon your capital, steadily over time. It will always be more than a bank interest would offer you, but putting your money into stocks and shares can be a risky business, and while you may win big, you could also lose all of your original investment. Day trading diggers from long term trading as it is lower risk.

Beginners Day Trading

Day trading is a lower risk form of trading, as you will not be leaving your money within the market over night. This means, that you will not risk your stocks and shares plummeting before you are able to trade again. With the development of the internet, and new regulations for ‘retail traders’ – day traders who are not part of banks and investment firms – you now have the possibility to make a significant sum of money by day trading.

Knowing that to make the most of my money, I would need to find out more about day trading, I took to the internet and began to search for coaching. It did not take long to find a series of courses which offered to teach the basics of day training. By using a little of my own money to train, I could trade for myself in the future, and watch my own money increase.

Day trading coaches are available online, usually with an interactive programme. You can undergo lessons online, will have access to help forums, and a coach who can advise you. Some also offer a demo account so you can practice before actually using your own money in the financial market. Having this ability will minimise your losses.

The other option, is finding a day trading coach who will invest your money for you. If you cannot spare the time to learn about day trading, or do not find watching the financial market enjoyable, then you can hire a day trading coach, who will use your money to trade for you. With this system, those who are new to day trading, will be able to gain a higher profit, as the coaches are experienced, where they are not.

Day trading is the practice of buying and selling commodities over the course of one day to take into account fluctuations of prices over the course of trading. It can be practiced in all commodity markets, despite the fact it is most commonly associated with the trade of shares, and scrap metal is no exception to that. Generally speaking, the theory behind day trading is that by buying stocks early in the day and selling when prices start to rise, the trader can turn a quick profit and repeat the formula over and over again. But how exactly do you go about day trading in scrap metal, and how easy is it to realise a profit overall?

Day Trading Rules

Before even considering getting involved in day trading you need to think about what you want to achieve and how want to get there. Are you looking to make a living out of day trading? It’s possible, but it will probably take time for you to learn the ropes, and it would certainly be unwise to give up your day job before you’ve got a proven track record of making money from your trade. Looking to make a bit of money on the side? Probably a more likely starting point for the beginner investor, and significantly more achievable initially than a full time goal. Secondly you need to consider how you want to go about trading ? whether you want to learn as you go the various tips and techniques for improving profitability, or whether you’re prepared to dedicate time and effort to learning what goes on first in theory before putting your money on the line. Either way is just as practical, yet it may be better to ensure you know what you’re doing first off if you’re not prepared to lose any money.

One of the most critical considerations that beginner investors overlook is portfolio diversification. Nine times out of ten, the beginner will invest all his day’s money in one material in the hope of making a profit ? sort of ?all or bust? thinking. However, by spreading your investment across a number of different metals you can spread the risk associated with losses on one type of metal, and increase the likelihood of a profit overall from your day’s trading in scrap metal. That’s the importance of diversification ? don’t put all your eggs in one basket.

Day trading can be an exciting a fun hobby, yet it can also be a very profitable one if you take the time to find out what you need to know and learn from the rookie mistakes you will inevitably make. Don’t set your sights too high initially ? just be prepared to get in there and turn a profit, with a view to building up some trading capital for making serious money later down the line with your scrap metal trading endeavours to supplement your current income or provide a steady revenue stream from full time or part time trading.

More information can be found here:

 

About 

Jan de Wit is your forex and binary options blogger, bringing the best free tips, tools, ebook and more to his subscribers at his site.